China chinese patent medicine industry report, 2010

China Chinese Patent Medicine Industry Report, 2010 Dec. 2010

[object Object],[object Object],[object Object],Please visit our website to order this report and find more information about other titles at www.researchinchina.com Related Products China Heparin Industry Report, 2010 China Pharmaceutical Chain Industry Report, 2010 China Chemical Pharmaceutical Industry Report, 2009-2010 China Hemodialysis Industry Report, 2009-2010 China Orthopedic Instrument Industry Report, 2009-2010 China PTCA Balloon Catheter Market Investment Report, 2009-2010

[object Object],[object Object],Abstract China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world. Driven by both policy incentives and market demand, Chinese patent medicine has developed well in China. From 2006 to 2009, China’s industrial output value and sales revenue of Chinese patent medicine grew at annual rates of 13.9% and 12.7% respectively. The terminal sales revenue of Chinese patent medicine has always accounted for about 30% of the total pharmaceutical revenue of China since 2006. As of August 2010, there had been 1,522 Chinese patent medicine manufacturers in China, including over 30 listed companies, such as Tasly, Tongrentang and Yunnan Baiyao; there had been over 10,000 kinds of Chinese patent medicine, such as Tasly’s Compound Danshen Dripping Pill (Fu Fang Dan Shen Di Wan), Tongrentang’s Bolus of Six Drugs Including Rehmannia (Liu Wei Di Huang Wan) and Bolus of Black-bone Chicken (Wu Ji Bai Feng Wan); there had been over 40 dosage forms, such as traditional bolus, ointment, powder and pellet as well as modern capsule, tablet and spray.

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],As China’s Chinese patent medicine has gained increasing International recognition and high profit (generally, the operating profit margin is above 70%), and the chemical and pharmaceutical industry has encountered development bottlenecks, global pharmaceutical giants and related institutions have marched into China’s Chinese patent medicine-related fields through joint venture, sole proprietorship or other forms. For example, Novartis and Kunming Pharmaceutical signed a General Agreement on Patent Development Permit for the R & D and production of artemether raw materials, U.S. National Institutes of Health (NIH) (the world's largest medical research institute and research fund management institution) and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited signed a cooperative agreement on the research of anti-virus mechanism of Baiyunshan Radix Isatidis Granule. Due to the particularity of Chinese patent medicine market, manufacturers generally can only set foot in some market segments instead of all application fields of Chinese patent medicine. Moreover, as there are a lot of manufacturers engaged in Chinese patent medicine, the competition among them is intense, and the market concentration is low even in market segments.

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],1. Overview of Chinese Patent Medicine 1.1 Definition and Classification 1.2 Comparison among Chinese Patent Medicine, Herbal Medicine and Natural Medicine 1.3 Industry Chain 2. Market Operating Environment for China’s Chinese Patent Medicine 2.1 Global Environment 2.1.1 Polices 2.1.2 Market Status 2.1.3 Development Trend 2.2 Domestic Environment 2.2.1 Polices 2.2.2 Operation of TCM Industry 3. Overview of China’s Chinese Patent Medicine Market 3.1 Status Quo 3.2 Supply and Demand 3.2.1 Supply 3.2.2 Demand 3.3 Competition 3.4 Import & Export 3.4.1 Export 3.4.2 Import 3.5 Development Prospect and Trend 3.5.1 International Market 3.5.2 Domestic Market 3.5.3 Influence of Raw Materials Table of contents 5.6.2 Operation 5.6.3 Development Prospect and Advantages 5.7 Kunming Pharmaceutical 5.7.1 Profile 5.7.2 Operation 5.7.3 Development Prospect and Advantages 5.8 CONBA 5.8.1 Profile 5.8.2 Operation 5.8.3 Development Prospect and Advantages 5.9 Tongrentang 5.9.1 Profile 5.9.2 Operation 5.9.3 Development Prospect and Advantages 5.10 Guilin Sanjin 5.10.1 Profile 5.10.2 Operation 5.10.3 Development Prospect and Advantages

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Selected Charts

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Selected Charts

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Selected Charts

[object Object],[object Object],[object Object],[object Object],[object Object],Choose type of format Hard copy ………………………1500 USD PDF (Single user license) ………...1400 USD PDF (Enterprisewide license)….. ...2100 USD ※ Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via Paypal. Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● [email_address] How to Buy Party A: Name: Address: Contact Person: Tel E-mail: Fax Party B: Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina) Address: Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Contact Person: Liao Yan Phone: 86-10-82600828 E-mail: [email_address] Fax: 86-10-82601570 Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No # : 332906 Bank SWIFT Code: COMMCNSHBJG Title Format Cost Total

China chinese patent medicine industry report, 2010

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Semelhante a China chinese patent medicine industry report, 2010

Semelhante a China chinese patent medicine industry report, 2010 (20)

Mais de ResearchInChina

Mais de ResearchInChina (20)

China chinese patent medicine industry report, 2010